New findings on post-chemotherapy deaths using world-first PHE cancer dataOctober 19, 2016 // No Comments
Public Health England recently reported that the first major report using world-first systemic anticancer treatment (SACT) data had been published by Lancet Oncology. The report shows that age, general wellbeing and other factors can affect 30-day mortality following chemotherapy for breast and lung cancer. The data gives new insights about the real-world chemotherapy treatment of patients in the NHS in England which was previously only available from clinical trials. In 2014 alone, the dataset included over 2 million records for over 160,000 different patients.
The main findings were:
- Most of the people who died within 30 days were receiving palliative treatment (where the cancer cannot be cured and chemotherapy is given to relieve symptoms and improve quality of life.
- There were also a small number of deaths in those patients given treatment with the intention to cure.
- There were no clusters of these deaths, they were scattered across 53 different Trusts.
- Older patients with more advanced disease, who also had other illnesses and a worse performance status, were more likely to die.
- Patients with a high body mass index (BMI) were less likely to die than those with a low BMI.
- Patients were most likely to die when being given their first round of chemotherapy.